

#	Year approved/awarded	PSG Proposal approved/awarded (2006-present)	PIs	Funding source	PSG Database requested
1	2007	ELLDOPA Database Analysis	Robert Hauser; D. Oakes	Private	ELLDOPA
2	2007	Prognostic Factors in Early PD	Connie Marras/Lang	Funded by MJFF	PRECEPT
3	2007	Defining PD Subtypes Based on Patterns of Long-Term Outcome	Robert Hauser; M. McDermott	Funded by MJFF	DATATOP and CALM-PD and their extensions
4	2007	Prediction of Death, Dementia, Disability, Depression from the Time Course of UPDRS Motor Status	Jay Nutt/Holford	Funded by MJFF	DATATOP; added ELLDOPA, TEMPO and CALM
5	2007	Predictors and Course of Cognitive Decline and Depression Early in the Course of PD based on the DATATOP Cohort	Ergun Uc; Mike McD	PSG/PDF (06-07)	DATATOP
6	2007	Predicting PD Progression Subtypes by CSF Urate Pathways	Schwarzschild; Ascherio; D. Oakes	PSG/PDF (06-07)	DATATOP CSF samples
7	2007	Using human cerebrospinal fluid samples collected in DATATOP study for biomarker discovery in patients with PD	Zhang, Jing Biostats: Mike McD, Peggy A.	PSG/PDF (06-07)	DATATOP CSF samples
8	2007	Environmental exposures modifying clinical expression of LRRK2-associated PD	Connie Marras; Tanner, Lang	PSG/PDF (07-08)	not a data-mining project
9	2007	Weight loss in PD	Ergun Uc; D. Oakes, co-PI	PSG/PDF (07-08)	DATATOP, CALM-PD, PRESTO
10	2007	Randomized clinical trial of oral inosine for PD (SURE-PD)	Michael Schwarzschild	Funded by MJFF	N/A
11	2008	An exploratory analysis of genetic risk factors for PD dementia in the DATATOP cohort	Karen Marder; M. McDermott	Private	DATATOP DNA samples

12	2008	A pilot Phase II double blind...early efficacy study of isradipine as a disease modifying agent in patients with early PD (STEADY-PD)	Tanya Simuni	Funded by MJFF	N/A
13	2008	Vitamin D insufficiency: Prevalence and Clinical Correlates in the DATATOP cohort	Marian Evatt	PSG/PDF (07-08)	DATATOP serum samples
14	2008	Impact of commonly-prescribed medications on PD progression	Andrew Siderowf; D. Oakes	NPF	PRECEPT, TEMPO, CALM-PD, QE-2, ELLDOPA
15	2008	Determination of Minimally Clinically Important Change in Early and Advanced PD	Robert Hauser; Peggy A. co-PI	PSG/PDF (08-09)	TEMPO and PRESTO
16	2008	Urate-related genes and PD progression	Alberto Ascherio; D. Oakes	NIH/NINDS; April 2009	DATATOP and PRECEPT DNA
17	2008- trial terminated	A Randomized, db, placebo-controlled study to assess the efficacy & safety of 3 doses of Aplindore MR in patients with early PD (APLIED)	Ira Shoulson	Neurogen Corp.	N/A
18	2008	Longitudinal Assessment and Biomarkers Study in PD (LABS-PD): A concept pre-proposal	Ira Shoulson	NIH and others	N/A
19	2009	Antidepressant Induced Delay of Motor Symptoms in PD (AIDS-PD)	Timothy Collier/Katrina Paumier	PSG/PDF (08-09)	TEMPO, ELLDOPA, QE2, PRECEPT, FS1 and FSTOO
20	2009	Pigmentation genes and PD progression	X. Gao; A. Ascherio	N/A	DATATOP DNA samples
21	2009	Evaluation of Blood Biospectroscopy as a Novel Biomarker of Idiopathic PD (SPIN-PD)	A. Lang/B. Ravina	Funded by MJFF	N/A
22	2009	Levodopa-Induced Motor Fluctuations and Dyskinesias in PD Subjects: Clinical Risk Factors	P. LeWitt	N/A	DATATOP and CALM-PD
23	2009	Serum urate and PD progression; secondary analyses of the CALM-PD cohort	M. Schwarzschild	Multiple funding sources	CALM-PD
24	2009	Retinal Thickness in PD	I. Bodis-Wollner	NIH proposed	N/A

25	2009	Detection of biomarkers in LRRK2+ PD	T. Foroud	NIH	N/A
26	2009	Metabolomic Analysis of PD CF	P. LeWitt	MJFF	DATATOP CSF, clinical and demographic data
27	2009	Peripheral Markers of PD: The Xanthine Connection	P. LeWitt	MJFF	DATATOP blood and urine specimens, clinical and demographic data
28	2009	Serum cholesterol level as a predictor of progression in PD	Xuemei Huang	PSG/PDF (09-10)	DATATOP and PRECEPT
29	2009	Exercise as Disease Modifying Treatment in Early PD	R. Kurlan	NIH proposed	N/A
30	2010	The role of motor learning in dopaminergic therapy of PD	Un Kang	PSG/PDF (09-10)	ELLDOPA and PATCH
31	2010	LRRK2 Mutations: Environmental & Genetic Modifiers of Penetrance & Expressivity (GEM-PD)	C. Marras; C. Tanner	NIH proposed	PSG sites
32	2010	PD Genome-Wide Association Studies (GWAS) Consortium - DATATOP Sample Request	T. Foroud	NIH proposed	DATATOP DNA samples
33	2010	Phase III db placebo controlled parallel group study of isradipine CR as a disease modifying agent in patients with early PD. (Next phase of STEADY-PD trial)	T. Simuni	NINDS	N/A
34	2010	An Exploration of the Association of Inflammatory Cytokines and the Non-Motor Symptoms of PD in Patients in DATATOP	M. Menza	PSG/PDF (10-11)	DATATOP serum samples
Mentored Clinical Research Awardees					
35	2004-05	Antidyskinetic properties of topiramate: A double-blind, placebo-controlled trial in patients with PD and levodopa-induced dyskinesias	Wendy Galpern	PSG/PDF	N/A

36	2005-06	A family study of LRRK2 mutations: Establishing evaluation and screening methods	Connie Marras	PSG/PDF	N/A
37	2006-07	Defining the prevalence and phenotype of the leucine-rich repeat kinase (LRRK2) in Ashkenazi Jews	Vicki Shanker	PSG/PDF	N/A
38	2007-08	Prospective study of diet quality, dietary urate index and survival of PD patients	Xiang Gao	PSG/PDF	N/A
39	2008-09	Prevalence and familial aggregation of panic disorder in patients with PD	Gregory Pontone	PSG/PDF	N/A
40	2009-10	A Pilot Study of Balance and Vitamin D in Persons with PD	Amie Peterson	PSG/PDF	N/A
41	2010-11	Nicotine Treatment of Impulsivity in PD: A Pilot Study	James Boyd	PSG/PDF	N/A